Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Peter C Reifsnyder"'
Publikováno v:
PLoS ONE, Vol 9, Iss 12, p e114324 (2014)
While rapamycin treatment has been reported to have a putatively negative effect on glucose homeostasis in mammals, it has not been tested in polygenic models of type 2 diabetes. One such mouse model, NONcNZO10/LtJ, was treated chronically with rapam
Externí odkaz:
https://doaj.org/article/93aef0a36d954748a96ff3aaf8135690
Autor:
Jake W. Willows, Morganne Robinson, Zahra Alshahal, Samantha K. Morrison, Gargi Mishra, Harrison Cyr, Magdalena Blaszkiewicz, Gilian Gunsch, Sabrina DiPietro, Emma Paradie, Benjamin Tero, Anne Harrington, Larisa Ryzhova, Lucy Liaw, Peter C. Reifsnyder, David E. Harrison, Kristy L. Townsend
Publikováno v:
Aging Cell
Cover legend: The cover image is based on the Research Article Age‐related changes to adipose tissue and peripheral neuropathy in genetically diverse HET3 mice differ by sex and are not mitigated by rapamycin longevity treatment by Jake W. Willows
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e85aa5dafb8023f319c0d3e98c135ca3
https://europepmc.org/articles/PMC10086519/
https://europepmc.org/articles/PMC10086519/
Autor:
Jake W. Willows, Morganne Robinson, Zahra Alshahal, Samantha K. Morrison, Gargi Mishra, Harrison Cyr, Magdalena Blaszkiewicz, Gilian Gunsch, Sabrina DiPietro, Emma Paradie, Benjamin Tero, Anne Harrington, Larisa Ryzhova, Lucy Liaw, Peter C. Reifsnyder, David E. Harrison, Kristy L. Townsend
Publikováno v:
Aging Cell. 22
Autor:
Peter C. Reifsnyder, Kevin Flurkey, Rosalinda Doty, Nigel A. Calcutt, Robert A. Koza, David E. Harrison
Publikováno v:
Aging cell, vol 21, iss 9
Rapamycin treatment has positive and negative effects on progression of type 2 diabetes (T2D) in a recombinant inbred polygenic mouse model, male NONcNZO10/LtJ (NcZ10). Here, we show that combination treatment with metformin ameliorates negative effe
Autor:
Gargi Mishra, Morganne Robinson, Harrison Cyr, Peter C. Reifsnyder, Jake W. Willows, David E. Harrison, Kristy Townsend
Publikováno v:
Circulation Research. 129
Energy homeostasis and adipose tissue metabolism are regulated in large part through peripheral sympathetic nerve innervation of metabolically important tissues and organs. This neural communication from the brain to adipose tissues results in releas
Autor:
Kevin Flurkey, Ian Mills, Peter C. Reifsnyder, Sergey Ryzhov, David E. Harrison, Rea P. Anunciado-Koza, Robert A. Koza
Publikováno v:
Annals of the New York Academy of Sciences. 1418:106-117
Rapamycin (RAPA), an inhibitor of mTORC signaling, has been shown to extend life span in mice and other organisms. Recently, animal and human studies have suggested that inhibition of mTORC signaling can alleviate or prevent the development of cardio
Publikováno v:
J Gerontol A Biol Sci Med Sci
Studies in mice suggest that rapamycin has a negative impact on glucose homeostasis by inducing insulin resistance. However, results have been inconsistent and difficult to assess because the strains, methods of treatment, and analysis vary among stu
Autor:
Peter C, Reifsnyder, Sergey, Ryzhov, Kevin, Flurkey, Rea P, Anunciado-Koza, Ian, Mills, David E, Harrison, Robert A, Koza
Publikováno v:
Annals of the New York Academy of Sciences. 1418(1)
Rapamycin (RAPA), an inhibitor of mTORC signaling, has been shown to extend life span in mice and other organisms. Recently, animal and human studies have suggested that inhibition of mTORC signaling can alleviate or prevent the development of cardio
Autor:
Marjorie Strobel, Andrew Schile, Peter C. Reifsnyder, David Schultz, Edward H. Leiter, Adam O'Neill
Publikováno v:
Journal of Diabetes Research, Vol 2013 (2013)
Journal of Diabetes Research
Journal of Diabetes Research
This review compares two novel polygenic mouse models of type 2 diabetes (T2D), TALLYHO/JngJ and NONcNZO10/LtJ, and contrasts both with the well-known C57BLKS/J-Leprdb(db/db) monogenic diabesity model. We posit that the new polygenic models are more
Publikováno v:
Aging (Albany NY)
Numerous studies suggest that rapamycin treatment promotes insulin resistance, implying that rapamycin could have negative effects on patients with, or at risk for, type 2 diabetes (T2D). New evidence, however, indicates that rapamycin treatment prod